Non-specific activation of human eosinophil functional responses by vasoactive intestinal peptide

Allergology International

Volumn 49, Issue 1, 2000, Pages 19-26

  El Shazly, Amr ^a,b   Masuyama, Keisuke ^a   Tsunoda, Noriaki ^a   Euro, Masao ^a   Ishikawa, Takeru ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Allergic inflammation; Eosinophil; Functional response; Signal transduction; Vasoactive intestinal peptide

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

ALLERGY; ARTICLE; CELL ACTIVATION; ENZYME ACTIVITY; EOSINOPHIL; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE MIGRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0034108739     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1592.2000.00154.x     Document Type: Article

References (30)

1. Motojima S, Frigas E, Leogering DA, Gleich GJ. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am. Rev. Respir. Dis. 1989; 139: 801-5.
2. Ayras GH, Altman LC, MacManus MM et al. Injurious effect of the eosinophil peroxide-hydrogen peroxide-halide system and major basic protein on human nasal epithelium in vitro. Am. Rev. Respir. Dis. 1989; 140: 125-31.
3. Agosti JM, Altman LC, Ayras GH, Loegering DA, Gleich GJ, Klebanoff SJ. The injurious effect of eosinophil peroxide peroxidase, hydrogen peroxide, and halides on pneumocytes in vitro. J. Allergy Clin, Immunol. 1987; 79: 496-504.
4. El-Shazly AE, Masuyama K, Eura M, Ishikawa T. Immunoregulatory role of substance P in human eosinophil migratory function, Immunol. Invest. 1996; 25: 191-201.
5. El-Shazly AE, Masuyama K, Ishikawa T. Mechanisms involved in activation of human eosinophil exocytosis by substance P: An in vitro model of sensory neuroimmunomodulation. Immunol. Invest. 1997; 26: 615-29.
6. Numao T, Agrawal DK. Neuropeptides modulate human eosinophil chemotaxis. J. Immunol. 1992; 149: 3309-15.
7. Uden BJ, Dick EC, Buckner CK. Inhibition by vasoactive intestinal peptide of antigen-induced histamine release from guinea pig minced lung. Eur. J. Pharmacol. 1983; 88: 247-50.
8. Said SI. Neuropeptides as modulators of injury and inflammation. Life Sci. 1990; 47: PL19-20.
9. Ghatei MA, Sheppard M, O'Shaughnessy DJ et al. Regulatory peptides in the mammalian respiratory tract. Endocrinology 1982; 111: 1248-54.
10. Baraniuk JN, Okayama M, Lundgren JD et al. Vasoactive intestinal peptide in human nasal mucosa. J. Clin. Invest. 1990; 86: 825-31.
11. Mosimann BL, White MV, Hohman RJ, Goldrich MS, Kaulbach HC, Kaliner MA. Substance P, calcitonin generelated peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. J. Allergy Clin, Immunol. 1993; 92: 95-104.
12. Said SI. Vasoactive peptides in the lung, with special reference to vasoactive intestinal peptide. Exp. Lung Res. 1982; 3: 343-8.
13. Palmer JBD, Cuss FMC, Barnes PJ. VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airway. J. Appl. Physiol. 1986; 61: 1322-8.
14. Peatfield AC, Barnes PJ, Bratcher C, Nadel JA, Davis B. Vasoactive intestinal peptide stimulates tracheal submucosal gland secretion in ferret. Am. Rev. Respir. Dis. 1983; 128: 89-93.
15. Stjarne P, Lacroix JS, Anggard A, Lundberg JM. Compartment analysis of vascular effects of neuropeptides and capsaicin in the pig nasal mucosa. Acta Physiol. Scand. 1991; 141: 335-42.
16. Delgado M, de la Fuente M, Martinez C, Gomariz RP. Pituitary abenylate cyclase-activating polypeptides inhibit the mobility of murine thymocytes and splenic lymphocytes: Comparison with and implication of cAMR J. Neuroimmunol. 1995; 62: 137-46.
17. O'Dorisio MS, Shannaon BT, Fleshman DJ, Campolito LB. Identification of high affinity receptors for vasoactive intestinal peptide on human lymphocytes of B cell lineage. J. Immunol. 1989; 142: 3533-6.
18. Lopez AF, Sanderson CJ, Gamble JR, Campell HD, Ypung IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J. Exp. Med. 1988; 167: 219-24.
19. Hakansson L, Vengue P. Priming of eosinophil and neutrophil migratory responses by interleukin 3 and interleukin 5.APMIS 1994; 102: 308-16.
20. Hansel TT, de Vries IJM, Iff T et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J. Immunol. Methods 1991; 145: 105-10.
21. El-Shazly AE, Masuyama K, Samejima Y, Eura M, Ishikawa T. Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate. Immunopharmacol. Immunotoxicol. 1996; 18: 587-95.
22. Eura M, Ogi K, Chikamatsu K et al. Expression of the mage gene family in human head and neck squamous cell carcinomas. Int. J. Cancer 1995; 64: 304-8.
23. Park SK, Olsen TA, Ercal N, Summers M, O'Dorisio MS. Characterization of vasoactive intestinal peptide receptors on human megakaryocytes and platelets. Blood 1996; 87: 4629-35.
24. Zheng ZM, Specter S. Dynamic production of tumour necrosis factor-alpha messenger RNA, intracellular and extracellular TNF-alpha by murine macrophages and possible association with tyrosine phosphorylation of STAT 1 alpha and ERK2 as an early signal. Immunology 1996; 87: 544-50.
25. Yasui K, Yamazaki M, Miyabayashi M, Tsuno T, Komiyama A. Signal transduction pathway in human polymorphonuclear leukocytes for chemotaxis induced by a chemotactic factor. J. Immunol. 1994; 152: 5922-9.
26. 2 and vanadate stimulate protein tyrosine phosphorylation in intact cells. J. Biol. Chem. 1990; 265: 2896-906.
27. Pandol SJ, Kiertisin D, Mari SS, Walie V, Jean R. Vasoactive intestinal peptide receptor antagonist (4 CI-D-Phe-Leu) VIP. Am. J. Physiol. 1986; 250: G553-7.
28. Kita H, Abu-Ghazaleh RI, Gleich GJ, Abraham RT. Role of pertussis toxin-sensitive G proteins in stimulus-dependent human eosinophil degranulation. J. Immunol. 1991; 147: 3466-73.
29. Kessel RGC, Roos D, Verhoeven AJ. fMet-Leu-Phe-induced activation of phospholipase D in human neutrophils. J. Biol. Chem. 1991; 266: 23 152-6.
30. 2+-dependent translation domain with homology to PKC and GAP. Cell 1991; 65: 1043-51.